Adeno-associated virus gene therapy for 21-hydroxylase deficiency
Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxylase (21OH) protein and related uses for treating 21OH deficiency.
1. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule, comprising (i) at least one AAV inverted terminal repeat (ITR) and (ii) a non-AAV nucleotide sequence encoding a 21-hydroxylase (21 OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein the non-AAV nucleotide sequence is operably linked to a CAG promoter, and wherein the rAAV particle is an AAV5 serotype.
2. The rAAV particle of claim 1 , wherein the 21OH protein is human 21OH protein.
3. The rAAV particle of claim 1 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of the human 21OH (CYP21A2) cDNA.
4. The rAAV particle of claim 3 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of a codon-optimized nucleotide sequence.
5. The rAAV particle of claim 1 , wherein the non-AAV nucleotide sequence encoding a 21OH protein;
(i) comprises or consists of SEQ ID NO:50, or
(ii) encodes the amino acid sequence of SEQ ID NO:1, or
(iii) encodes an amino acid sequence at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:1.
6. The rAAV particle of claim 1 , wherein the promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 2.
7. The rAAV particle of claim 1 , wherein the ITR is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, or rh74 serotype ITR.
8. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule comprising a non-AAV nucleotide sequence encoding a 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein:
(i) the non-AAV nucleotide sequence is operably linked to a CAG promoter;
(ii) the rAAV vector comprises at least one AAV inverted terminal repeat (ITR), wherein the ITR is from an AAV of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, or rh74; and
(iii) the rAAV particle is an AAV5 serotype.
9. A pharmaceutical composition comprising the rAAV particle of claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.
10. A method of producing an rAAV particle, the method comprising culturing a host cell containing: (a) the rAAV vector comprising a nucleic acid molecule, comprising (i) at least one AAV inverted terminal repeat (ITR) and (ii) a non-AAV nucleotide sequence encoding a 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein the non-AAV nucleotide sequence is operably linked to a CAG promoter; (b) a nucleic acid molecule encoding an AAV rep protein; (c) a nucleic acid molecule encoding at least one AAV capsid protein and (d) sufficient helper functions for packaging the rAAV particle, wherein the rAAV particle is an AAV5 serotype.
11. A method of expressing 21-hydroxylase (21OH) in a subject in need thereof, comprising providing a therapeutically effective amount of the rAAV particle of claim 1 to the subject, thereby expressing 21OH in the subject.
12. The method of claim 11 , wherein the 21OH is expressed in the subject's adrenal cortex, adrenal medulla, adrenal stem cells, adrenal progenitor cells, liver, or ovary.
13. A method of treating a subject with 21-hydroxylase deficiency (21OHD), comprising providing a therapeutically effective amount of the rAAV particle of claim 1 to the subject, thereby treating 21OHD in the subject.
14. The method of claim 13 , wherein the rAAV particle or a composition comprising the rAAV particle, is administered to the subject intravenously, by direct injection into the adrenal gland via open surgery or laparoscopy, or by injection into an adrenal artery via catheterization.
15. The method of claim 13 , wherein the subject is affected with congenital adrenal hyperplasia and/or the Prader stage IV or V form of 21OHD.
16. The rAAV particle of claim 1 , wherein the rAAV vector further comprises a Kozak sequence.
17. The rAAV particle of claim 1 , wherein the rAAV vector further comprises an miR-122 binding site.
18. The method of claim 11 , wherein the rAAV article, or a composition comprising the rAAV particle, is administered to the subject intravenously, by direct injection into the adrenal gland via open surgery or laparoscopy or by injection into an adrenal artery via catheterization.
19. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule, comprising a non-AAV nucleotide sequence encoding a human 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1 and an miR-122 binding site, wherein the non-AAV nucleotide sequence encoding a human 21-hydroxylase (21OH) protein is operably linked to a CAG promoter, and wherein the rAAV particle is an AAV5 serotype.
20. The rAAV vector of claim 19 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of a codon-optimized nucleotide sequence.